Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT02145546

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02145546
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02145546. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation
Acronym
ADA-PAF
Intervention (Drug)
Amiodarone
Intervention (Drug)
Propafenone
Intervention (Drug)
Sotalol
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (class: other)
Collaborator
Medtronic (Shanghai) Management Co. Ltd. (class: industry)
Collaborator
Beijing CTSmed Co. Ltd (class: not stated)

Record details

Record id
cardio:ct-nct02145546
Content hash
f7cd351a00b473fd1e3eadf3da9840cd482ca4980103c420f0995d4c514c9f93